Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Beam Therapeutics (BEAM)

NASDAQ: BEAM · Biotechnology—Gene Editing · Cambridge, MA

Our rating: Cautious

Cautious reaffirmed at $29.07, moderate conviction, August 19, 2026.

Breaks if: The Cautious view would be proven wrong if Beam reports trailing annual revenue above $250 million with free cash flow burn narrowing below $200 million within the next four quarterly filings — conditions that would indicate the collaboration pipeline is converting at genuine scale and that cash consumption is moving toward a sustainable level. In price terms, a sustained move above $40 within twelve months, accompanied by a real improvement in the free cash flow profile, would constitute clear invalidation.

Key figures

Market value$2.2B
Revenue, last 12 months$147M
Net income, last 12 months−$108M
Free cash flow, last 12 months−$398M
Price to earningsn/a
Free cash flow yield−18.4%
Dividend yield0.0%
Operating margin−267.7%
Return on equity−11.3%
Beta to the S&P 5001.82
Volatility, annualized72.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$307000.00−96.8%$-1.28−$112M
June 30, 2026$490000.00−94.2%$-1.18−$69M
March 31, 2026$32M324.9%$-0.91−$131M
December 31, 2025$114M279.5%$2.50−$87M
September 30, 2025$10M−32.0%$-1.10−$86M
June 30, 2025$8M−28.1%$-1.00−$80M
March 31, 2025$7M0.8%$-1.23−$107M
December 31, 2024$30M−90.5%$-1.09−$79M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

21 ledger entries and 20 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.